Current anti-obesity therapies that suppress appetite often cause undesirable reductions in lean mass by indirectly depleting systemic energy store. In this study, we developed a novel anti-obesity drug, Vutiglabridin (VUTI), designed to selectively reduce fat mass while preserving lean mass. We eva...
ORGANISM(S): Mus Musculus (mouse)
